A Method to Isolate Tumor Specific T-Cells or T-Cell Receptors from Peripheral Blood using In-vitro Stimulation of Memory T-Cells
Adoptive cell transfer (ACT) and T-cell receptor (TCR) therapies use lymphocytes that target somatic mutations expressed by tumors cells to treat cancer patients. One of the challenges of these therapies is the identification and isolation of mutation-specific cells and TCRs. While neoantigen specific cells are relatively abundant in the tumor, they are far less common in peripheral blood, a more accessible source of T cells.
Researchers at the National Cancer Institute (NCI) have developed a method to isolate neoantigen specific cells or TCRs from selected populations of peripheral T-cells by performing in-vitro stimulation (IVS) on autologous memory T-cells. These cells have been stimulated by their cognate antigens at the tumor site or its draining lymph nodes, and therefore are more relevant for clinical use.
The NCI, Surgery Branch, is seeking licensing and/or co-development research collaborations for the development of a method to isolate tumor specific T-cells or T-cell receptors from peripheral blood. For collaboration opportunities, please contact Steven A. Rosenberg, M.D., Ph.D. at sar@nih.gov.
Potential Commercial Applications: | Competitive Advantages: |
|
|
Development Stage:
Discovery (Lead Identification)
Related Invention(s):
E-085-2013
E-149-2015
Inventors:
Gal Cafri (NCI) ➽ more inventions...
Steven Rosenberg (NCI) ➽ more inventions...
Intellectual Property:
Application No. PCT/US2018/063563
Publications:
Cafri G, et al. Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients. PMID 30683863
Collaboration Opportunity:
Licensing and research collaboration
Licensing Contact:
John Hewes, Ph.D.
Email: John.Hewes@nih.gov
Phone: 240-276-5515
OTT Reference No: E-238-2017
Updated: Jun 28, 2019